Charles River Laboratories International, Inc. has announced it will release its financial results for the second quarter of 2026 before the U.S. stock market opens on August 5th. Following the release, the company's management will host a conference call at 9:00 a.m. that day to discuss the performance and provide a business update.
Charles River Laboratories is a globally prominent provider of drug discovery and non-clinical development services. Its operations are divided into three main segments: the production and sale of research models, drug discovery and safety assessment services, and manufacturing solutions. The company offers essential products and services to pharmaceutical and biotechnology firms, as well as academic institutions worldwide, supporting them from the early stages of discovery through to drug production.
Market attention for this earnings report is primarily focused on key metrics previously guided by management. The company had previously forecast that second-quarter reported revenue would decline by a mid-to-high single-digit percentage, with organic revenue expected to fall by a low single-digit amount. For earnings per share (EPS), the company projected at least a 30% sequential increase from the first quarter's $2.06. In late May, the analysis firm Zacks Research revised its Q2 EPS estimate downward from $2.85 to $2.72, while maintaining its full-year outlook, projecting EPS of $10.91 for the 2026 fiscal year.
The company has previously reaffirmed its full-year 2026 guidance, anticipating organic revenue to decline between 0.5% and 1.5%, with non-GAAP EPS expected in the range of $10.80 to $11.30. Management also forecasts an operating margin expansion of approximately 120 to 150 basis points for the full year, with the majority of the benefit expected to materialize in the second half. The company has completed the acquisitions of K.F. Cambodia assets and PathoQuest, and has divested certain non-core businesses, actions aimed at focusing on core testing services and improving profitability.